Veronica Teleanu
Overview
Explore the profile of Veronica Teleanu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohrmann L, Werner M, Oles M, Mock A, Uhrig S, Jahn A, et al.
Nat Commun
. 2022 Aug;
13(1):4485.
PMID: 35918329
The benefit of molecularly-informed therapies in cancer of unknown primary (CUP) is unclear. Here, we use comprehensive molecular characterization by whole genome/exome, transcriptome and methylome analysis in 70 CUP patients...
2.
Jaramillo S, Hennemann H, Horak P, Teleanu V, Heilig C, Hutter B, et al.
EJHaem
. 2022 Jul;
2(1):139-142.
PMID: 35846099
T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive T-cell malignancy. Chemotherapy alone cures only 25-45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed...
3.
Heilig C, Lassmann A, Mughal S, Mock A, Pirmann S, Teleanu V, et al.
Eur J Cancer
. 2022 Jun;
172:107-118.
PMID: 35763870
Background: The multi-receptor tyrosine kinase inhibitor pazopanib is approved for the treatment of advanced soft-tissue sarcoma and has also shown activity in other sarcoma subtypes. However, its clinical efficacy is...
4.
Horak P, Leichsenring J, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, et al.
Pathologe
. 2021 Oct;
42(6):602.
PMID: 34605937
No abstract available.
5.
Dohner H, Symeonidis A, Deeren D, Demeter J, Sanz M, Anagnostopoulos A, et al.
Hemasphere
. 2021 Aug;
5(8):e617.
PMID: 34350385
In this phase 3 trial, older patients with acute myeloid leukemia ineligible for intensive chemotherapy were randomized 2:1 to receive the polo-like kinase inhibitor, volasertib (V; 350 mg intravenous on...
6.
Horak P, Leichsenring J, Goldschmid H, Kreutzfeldt S, Kazdal D, Teleanu V, et al.
Genes Chromosomes Cancer
. 2021 Jul;
61(6):303-313.
PMID: 34331337
Modern concepts in precision cancer medicine are based on increasingly complex genomic analyses and require standardized criteria for the functional evaluation and reporting of detected genomic alterations in order to...
7.
Horak P, Heining C, Kreutzfeldt S, Hutter B, Mock A, Hullein J, et al.
Cancer Discov
. 2021 Jun;
11(11):2780-2795.
PMID: 34112699
The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a...
8.
Horak P, Leichsenring J, Kreutzfeldt S, Kazdal D, Teleanu V, Endris V, et al.
Pathologe
. 2021 May;
42(4):369-379.
PMID: 33938987
Increasingly extensive genomic diagnostics in cancer precision medicine require uniform evaluation criteria for the classification of variants with regard to their functional and therapeutic implications. In this review we present...
9.
Hubschmann D, Jopp-Saile L, Andresen C, Kramer S, Gu Z, Heilig C, et al.
Genes Chromosomes Cancer
. 2020 Nov;
60(5):314-331.
PMID: 33222322
Different mutational processes leave characteristic patterns of somatic mutations in the genome that can be identified as mutational signatures. Determining the contributions of mutational signatures to cancer genomes allows not...
10.
Heilig C, Horak P, Lipka D, Mock A, Uhrig S, Kreutzfeldt S, et al.
Genes Chromosomes Cancer
. 2020 Jun;
59(10):601-608.
PMID: 32501622
Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors of the gastrointestinal tract. Inactivating mutations or epigenetic deregulation of succinate dehydrogenase complex (SDH) genes are considered defining features of...